The DOI matches its Crossref record.
Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis
Abstract
MS is an immunologically mediated disease, as determined by observation of the response to immunotherapy and the existence of an animal model, experimental autoimmune encephalitis. Interferon (IFN) beta-1b, IFN beta-1a, and glatiramer acetate, the therapies used for relapsing or remitting MS, have mechanisms of action that address the immunologic pathophysiology of MS. The IFNs bind to cell surface-specific receptors, initiating a cascade of signaling pathways that end with the secretion of antiviral, antiproliferative, and immunomodulatory gene products. Glatiramer acetate, a synthetic molecule, inhibits the activation of myelin basic protein-reactive T cells and induces a T-cell repertoire characterized by anti-inflammatory effects. Although the two classes of drugs have some overlapping mechanisms of action, the IFNs rapidly block blood-brain barrier leakage and gadolinium (Gd) enhancement within 2 weeks, whereas glatiramer acetate produces less rapid resolution of Gd-enhanced MRI activity. IFN beta has no direct effects in the CNS, but glatiramer acetate-specific T cells are believed to have access to the CNS, where they can exert anti-inflammatory and possibly neuroprotective effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 58
- 10.1038/ni0901-785 · DOI
- 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q · DOI
- 10.1023/A:1012128406432 · DOI
- Allain H, Schuck S. Observations on differences between interferons used to treat multiple sclerosis. J Clin Res . 1998; 1: 381–392.
- 10.1212/WNL.46.6.1639 · DOI
- 10.1212/WNL.51.3.738 · doi:10.1212/wnl.51.3.738
- 10.2165/00044011-199918010-00004 · DOI
- 10.1212/WNL.56.2.148 · DOI
- 10.1212/WNL.53.4.679 · DOI · Paper page
- 10.1212/WNL.54.11.2055 · DOI
- 10.1177/135245859700300609 · DOI
- 10.1212/WNL.51.3.682 · DOI · Paper page
- 10.1056/NEJM200007133430207 · DOI · Paper page
- 10.1212/WNL.37.7.1097 · DOI · Paper page
- 10.1016/0165-5728(95)00072-A · DOI
- 10.1172/JCI119455 · DOI · Paper page
- 10.1046/j.1365-3083.2000.00688.x · DOI
- 10.1016/S0165-5728(98)00271-9 · DOI
- 10.4049/jimmunol.165.1.548 · DOI
- 10.1002/ana.1096 · DOI · Paper page
- 10.1212/WNL.48.5.1446 · DOI
- 10.1016/S0165-5728(96)00156-7 · DOI
- 10.1002/ana.410410517 · DOI
- 10.1016/0165-5728(95)00054-6 · DOI
- 10.1093/brain/122.7.1261 · DOI
- 10.1212/WNL.53.7.1397 · DOI · Paper page
- 10.1002/ana.410400607 · DOI · Paper page
- 10.1002/ana.410400606 · DOI · Paper page
- 10.1212/WNL.53.7.1380 · DOI
- 10.1016/0165-5728(91)90054-B · doi:10.1016/0165-5728(91)90054-b
- 10.1016/S0165-5728(97)00034-9 · DOI · Paper page
- 10.1177/135245859600200403 · doi:10.1177/135245859600200403
- 10.1126/science.279.5355.1344 · DOI · Paper page
- 10.1073/pnas.92.16.7440 · DOI · Paper page
- 10.1212/WNL.56.1.74 · DOI
- 10.1016/S0065-2776(08)60273-4 · DOI · Paper page
- 10.1016/0165-2478(96)02506-0 · DOI
- 10.1002/eji.1830010406 · DOI · Paper page
- 10.1056/NEJM198708133170703 · DOI · Paper page
- 10.1212/WNL.45.7.1268 · DOI · Paper page
- 10.1212/WNL.56.6.702 · DOI · Paper page
- 10.1212/WNL.55.11.1704 · DOI · Paper page
- 10.1073/pnas.96.2.634 · DOI · Paper page
- 10.1073/pnas.97.21.11472 · DOI · Paper page
- 10.1146/annurev.immunol.15.1.297 · DOI · Paper page
- 10.1177/135245850100700401 · DOI
- 10.1073/pnas.97.13.7446 · DOI · Paper page
- 10.1212/WNL.57.4.731 · DOI · Paper page
- 10.1002/ana.64 · DOI · Paper page
- 10.1212/WNL.50.3.701 · DOI · Paper page
- 10.1016/S0165-5728(98)00191-X · DOI · Paper page
- 10.1016/0165-5728(95)00085-G · doi:10.1016/0165-5728(95)00085-g
- 10.1002/1531-8249(200001)47:1<127::AID-ANA22>3.0.CO;2-1 · doi:10.1002/1531-8249(200001)47:1<127::aid-ana22>3.0.co;2-1
- 10.1212/WNL.56.2.148 · DOI
- Dhib-Jalbut S, Chen M, Costello K, Panitch H. Effect of combined IFN beta-1a and glatiramer acetate (GA) therapy on GA-T-cell responses in MS. Neurology . 2001; 56 (suppl 3): A225.Abstract.
- 10.1002/jnr.490280213 · DOI · Paper page
- Antel JP, Biernacki K, Prat A. Migratory behavior of Th1 and Th2 T cells across human brain-derived endothelial cells. Neurology . 2000; 54 (suppl 3): A149.Abstract.
- 10.1126/science.7680493 · DOI · Paper page
Cited by
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Clinical Course of Multiple Sclerosis
Klineova, S., & Lublin, F. D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028928 · Cited by 401
Metadata
- Authors
- Dhib-Jalbut, S.
- Venue
- Neurology
- Published
- 2002-04-23
- Volume
- 58
- Issue
- 8_suppl_4
- Pages
- S3-9
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2111468824
- Cited by
- 184
- References
- 0
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. https://app.cochat.ai/papers/10.1212/wnl.58.8_suppl_4.s3
- The paper
- Dhib-Jalbut, S. (2002). Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. https://doi.org/10.1212/wnl.58.8_suppl_4.s3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.